For example, Zhu et al. (2015) revealed that the augmentation of endogenous amylin by chronic systemic administration of non-amyloidogenic amylin, or its clinical analog pramlintide, has beneficial effects against neuropathological and cognitive deficits in a mouse model of AD. This evidence concerns the gene IAPP and Cognitive impairment.